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during COVID-19 and at up to
6 months of convalescence
B cell changes seen during acute
COVID-19 were largely restored in
convalescence
T cells from convalescent COVID-
19 patients displayed persistent
changes
Lymphocyte signatures defined 3
convalescent patient groups, one
with poorer outcomesShuwa et al. examine lymphocyte characteristics in acute and convalescent
COVID-19 patients, detailing persistent alterations in lymphocyte phenotype up
to 6 months following hospital discharge. In this report, they identify 3 subgroups
of convalescent patients based on distinct lymphocyte signatures, with 1 subgroup
associated with poorer clinical outcomes.Shuwa et al., Med 2, 720–735




llClinical and Translational Report
Alterations in T and B cell function persist
in convalescent COVID-19 patients
Halima A. Shuwa,1,11 Tovah N. Shaw,1,2,11 Sean B. Knight,1,3 Kelly Wemyss,1 Flora A. McClure,1
Laurence Pearmain,4,5 Ian Prise,1 Christopher Jagger,1 David J. Morgan,1 Saba Khan,1 Oliver Brand,1
Elizabeth R. Mann,1,6 Andrew Ustianowski,7 Nawar Diar Bakerly,3 Paul Dark,5,10
Christopher E. Brightling,8 Seema Brij,9 CIRCO, Timothy Felton,5 Angela Simpson,5
John R. Grainger,1,12 Tracy Hussell,1,12 Joanne E. Konkel,1,12,13,* and Madhvi Menon1,12,*Context and significance
The coronavirus disease 2019
(COVID-19) pandemic, caused by
a novel coronavirus strain, has
resulted in >100 million infections
worldwide. Emerging evidence
suggests that some COVID-19
patients suffer persistent
symptoms, including fatigue,
fibrotic lung disease, and myalgia;
however, the long-term immune
response in these patients
remains ill-defined. Here, we
conducted an observational study
examining lymphocyte
populations in COVID-19 patients
during hospitalization and at up to
6 months of convalescence. We
identified a number of lymphocyte
alterations that persisted in
convalescent patients. Moreover,
the compilation of lymphocyte
parameters in convalescent
COVID-19 patients identified 3
distinct patient subgroups, with 1
subgroup associated with poorer
clinical outcome. Our study
outlines lymphocyte changes in
convalescent COVID-19 patients
associated with negative effects
on subsequent health.SUMMARY
Background: Emerging studies indicate that some coronavirus disease
2019 (COVID-19) patients suffer from persistent symptoms, including
breathlessness and chronic fatigue; however, the long-term immune
response in these patients presently remains ill-defined.
Methods:Here, we describe the phenotypic and functional characteris-
tics of B and T cells in hospitalized COVID-19 patients during acute dis-
ease and at 3–6 months of convalescence.
Findings: We report that the alterations in B cell subsets observed in
acute COVID-19 patients were largely recovered in convalescent pa-
tients. In contrast, T cells from convalescent patients displayed
continued alterations with persistence of a cytotoxic program evident
in CD8+ T cells as well as elevated production of type 1 cytokines and
interleukin-17 (IL-17). Interestingly, B cells from patients with acute
COVID-19 displayed an IL-6/IL-10 cytokine imbalance in response to
Toll-like receptor activation, skewed toward a pro-inflammatory pheno-
type. Whereas the frequency of IL-6+ B cells was restored in convales-
cent patients irrespective of clinical outcome, the recovery of IL-10+ B
cells was associated with the resolution of lung pathology.
Conclusions: Our data detail lymphocyte alterations in previously hos-
pitalized COVID-19 patients up to 6 months following hospital
discharge and identify 3 subgroups of convalescent patients based
on distinct lymphocyte phenotypes, with 1 subgroup associated with
poorer clinical outcome. We propose that alterations in B and T cell
function following hospitalization with COVID-19 could affect longer-
term immunity and contribute to some persistent symptoms observed
in convalescent COVID-19 patients.
Funding: Provided by UKRI, Lister Institute of Preventative Medicine,
the Wellcome Trust, The Kennedy Trust for Rheumatology Research,
and 3M Global Giving.
INTRODUCTION
The coronavirus disease 2019 (COVID-19) pandemic, caused by the emergence of a
novel coronavirus strain, has resulted at this time in >106 million infections and 2.3
million deaths worldwide. Infection with severe acute respiratory syndrome-corona-
virus-2 (SARS-CoV-2) has a plethora of consequences, ranging from mild influenza-
like symptoms to life-threatening and fatal acute respiratory distress syndrome.1,2 In
all cases, the pathology is underpinned by not merely the virus itself but also an720 Med 2, 720–735, June 11, 2021 ª 2021 The Author(s). Published by Elsevier Inc.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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OPEN ACCESSClinical and Translational Reportaberrant inflammatory host immune response. Research efforts detailing immune
parameters in patients with acute COVID-19 have significantly improved our under-
standing of the disease, highlighting profound alterations in the innate and adaptive
immune compartments.3–7 Lymphopenia and altered lymphocyte function have
been reported to correlate with disease severity,1,8 indicating key roles for T and
B cells in COVID-19 pathology.
Emerging evidence suggests that COVID-19 patients can develop a spectrum of
long-lasting symptoms, including chronic fatigue, myalgia, brain fog, fibrotic lung
disease, and pulmonary vascular disease.9–11 Although the immune response in
acute COVID-19 patients has been well characterized, the long-term consequences
of SARS-CoV-2 infection remain poorly understood. Since SARS-CoV-2-specific lym-
phocytes are likely critical for long-term protection against SARS-CoV-2 following
disease resolution, it is pivotal to understand their contribution to acute disease, re-
covery, and long-lasting post-COVID-19 symptoms. Groundbreaking studies are
demonstrating that antigen-specific responses to this virus can persist for several
months post-infection.12–15 However, given the vast numbers of previously infected
individuals across the globe, it is also vital to understand the impact of COVID-19 on
the phenotype and functional potential of all lymphocytes, not just those reactive to
SARS-CoV2. This will allow for a better understanding of the long-term effects of be-
ing hospitalized with COVID-19 on effective immunity. Long-term follow-up of Ebola
patients has outlined immune dysfunction persisting for up to 2 years of convales-
cence.16 Following much shorter periods of convalescence, individuals hospitalized
with influenza infection have been shown to exhibit continued elevation in CD8+
T cell activation and proliferation.17 Given the prolonged and profound immune dys-
regulation seen during acute SARS-CoV2 infection, there is a compelling need to
determine whether these alterations translate into longer-term immune alterations
and subsequent dysfunction in convalescent individuals.
Here, we examined lymphocytes in COVID-19 patients during hospitalization and in
convalescent patients over 6 months following hospital discharge. Specifically, we
examined lymphocyte characteristics in peripheral blood mononuclear cells
(PBMCs) from blood samples taken from COVID-19 patients within 7 days of hospi-
talization, at hospital discharge, and at up to 6 months post-hospital discharge.
Samples were collected as part of the Coronavirus Immune Response and Clinical
Outcomes (CIRCO) study based at 4 hospitals in greater Manchester, UK.5 Examina-
tion of these samples allowed us to ascertain changes to lymphocytes during acute
disease and upon convalescence in COVID-19 patients. We identify key alterations
in B cell populations in acute COVID-19 patients with severe disease, which indicate
that imbalances within the B cell compartment could contribute to COVID-19 dis-
ease severity. Specifically, we demonstrate that in severe COVID-19 patients, there
was a loss of transitional B cells and an expansion of double-negative memory B
cells. Moreover, B cells exhibited altered functionality with increased production
of interleukin-6 (IL-6) during acute disease, which was restored in convalescent pa-
tients. Intriguingly, B cell production of IL-10 was higher in convalescent patients
with good clinical outcomes compared to patients with poor outcomes. In line
with this, we also report changes within the CD4+ T cell compartment of acute
COVID-19 patients, specifically increases in T follicular helper cells (Tfh) that were
recovered in convalescent patients. In contrast, we outline persistent alterations in
the functional potential of CD8+ T cells, with T cells from convalescent patients
exhibiting elevated expression of a cytotoxic program and production of type 1 cy-
tokines. These data describe alterations to lymphocytes, detailing previously unde-
scribed imbalances within the B cell compartment associated with the severity ofMed 2, 720–735, June 11, 2021 721
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6 months of convalescence. Furthermore, compiling B and T cell immune parame-
ters from convalescent patients identified 3 patient subgroups, defined by (1)
increased cytotoxic T cells and T cell type 1 cytokine production, (2) high proportions
of memory, IgA+, and IgG+ B cells, and (3) the highest expression of trafficking mol-
ecules and increased proportions of naive B and T cells. It is noteworthy that the
convalescent group defined by the highest proportions of cytotoxic CD8+ T cells
and type 1 cytokine production was enriched in patients with a poorer outcome at
follow-up, defined by abnormal chest X-ray. Our study provides a deeper under-
standing of lymphocyte responses over the course of COVID-19 and into recovery,
highlighting persistent alterations in lymphocyte functionality in convalescent
COVID-19 patients up to 6 months following hospital discharge.
RESULTS AND DISCUSSION
Clinical characteristics
Between March 29 and July 15, 2020, we recruited patients during their in-patient
stay for COVID-19, who had clinical and lymphocyte data available and who were re-
cruited within 7 days of admission. ‘‘Convalescent’’ patients were recruited between
July 14 and October 2020 from outpatient clinical follow-up for COVID-19. Conva-
lescent patients are therefore classified as previously hospitalized COVID-19 pa-
tients who are clinically stable and have been discharged from any further inpatient
care. Convalescent patients were sampled between 53 and 180 days of convales-
cence. For convalescent patients sampled twice during their convalescence, they
were initially sampled between 67 and 180 days of convalescence and then sampled
between 20 and 113 days later (with the latest second sample being taken at day 201
following discharge). For convalescent disease samples, one patient was excluded
due to a significant coexisting pathology during inpatient admission for COVID-
19; all others were included in the analysis. The median age and overall gender pro-
portions were similar between acute and convalescent groups. There was a larger
proportion of severe patients within the convalescent group, reflecting that patients
with more severe disease were prioritized for limited face to face appointments in
participating trusts. The clinical characteristics of all of the patients recruited to
the study are summarized in Tables S1 and S2.
Altered B cell phenotypes in severe COVID-19 patients are restored upon
convalescence
In agreement with previously published studies,5,6 we report significantly reduced
circulating B cell frequencies in severe COVID-19 patients that were normalized in
convalescent patients (Figure 1A). Furthermore, increased Ki-67 expression (indica-
tive of proliferation) in hospitalized patients was not observed in convalescent
patients (Figures 1B and S1A). When characterizing B cell subsets based on the
expression of CD27 and immunoglobulin D (IgD), we saw an expansion of
CD27IgD double-negative (DN) memory B cells in severe COVID-19 patients
that was still present in convalescent patients (Figures 1C and 1D). No differences
in unswitched memory (USM), switchedmemory (SM), or naive B cells were observed
between the patient groups and controls. Further classification of B cell subsets into
transitional (CD24hiCD38hi) and mature (CD24intCD38int) B cells revealed a signifi-
cant reduction in transitional B cells in patients with severe COVID-19 that was
restored in convalescent patients (Figures 1E and 1F). A t-distributed stochastic
neighbor embedding (tSNE) representation of the data highlights proportions of
subsets in acute and convalescent COVID-19 patients (Figure 1G). Importantly,
CD27hiCD38hi plasmablasts were the only B cell subset expanded in all COVID-19
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OPEN ACCESS Clinical and Translational Reportpatients (Figures 1H and S1B). We found that the frequency of plasmablasts posi-
tively correlated with the expression of IgG and IgA, but not with IgM expression
by B cells in acute COVID-19 patients (Figures 1I, S1C, and S1D), providing further
evidence supporting an expansion of class-switched IgA and IgG antibodies in
COVID-19 patients.18–20
Examining B cell phenotypes in individual COVID-19 patients, and tracking them
longitudinally from acute hospitalization into convalescence, showed similar alter-
ations in B cell populations. Specifically, we observed a reduction in Ki-67+ B cells
and plasmablasts at convalescent time points compared to acute disease and a
trend toward an increase in transitional B cells (Figure S1E). Interestingly, tracking
individual patients from acute disease into convalescence revealed a decrease in
DN B cells, despite the global expansion of this subset observed in both severe
acute and convalescent patients (Figure S1F). These data highlight alterations in B
cell subsets during severe acute COVID-19 that are largely restored upon
convalescence.Convalescent COVID-19 patients retain phenotypically altered CD8+ T cells
Previous studies have detailed CD8+ and CD4+ T cell activation in COVID-19 pa-
tients.6,21–23 Here, we show that convalescent patients exhibited elevated propor-
tions of T effector memory cells positive for CD45RA (TEMRA; CD45RA+CCR7)
(Figures 2A–2C). Despite this, T cells from convalescent patients did not display
elevated expression of the proliferation marker Ki-67 (Figure 2D; see Figures S1G–
S1K for representative fluorescence-activated cell sorting (FACS) staining).6 CD8+
T cells from acute COVID-19 patients exhibit robust expression of a cytotoxic pro-
gram, with increases in perforin, granzyme, and CD107a expression in unstimulated
cells (Figures 2E–2G). Induction of this program was still evident in convalescent
patients, whose CD8+ T cells exhibited increased expression of both perforin and
granzyme (Figures 2E and 2F). However, the proportions of CD107a+ and Ki-67-
+GranzymeB+CD8+ T cells in convalescent patients were reduced compared to
those with acute COVID-19, suggesting that cytotoxic CD8+ T cells in convalescent
patients were no longer actively proliferating or degranulating (Figure 2G). Showing
the same pattern, longitudinal tracking of individual patients from their acute time
point into convalescence showed unchanged perforin and granzyme B expressionFigure 1. Alterations in B cell subsets during acute COVID-19 are recovered upon convalescence
(A) Cumulative data show ex vivo frequency of CD19+ B cells in healthy individuals (n = 38) and COVID-19 patients with mild (n = 24), moderate (n = 26),
and severe (n = 12) disease and at convalescence (n = 83).
(B) Cumulative data show Ki-67 expression by B cells in healthy individuals (n = 28) and COVID-19 patients with mild (n = 13), moderate (n = 15), and
severe (n = 9) disease and at convalescence (n = 75).
(C and D) Representative flow cytometry plots and cumulative data show frequencies of naive (CD27IgD+), unswitched memory (CD27+IgD+), switched
memory (CD27+IgD), and double-negative (CD27IgD) B cells in healthy individuals (n = 38–40) and COVID-19 with mild (n = 22–24), moderate (n =
25–26), and severe (n = 12–13) disease and at convalescence (n = 78–80).
(E and F) Representative flow cytometry plots and cumulative data show ex vivo frequency of CD24hiCD38hi transitional B cells and CD24intCD38int
mature B cells in healthy individuals (n = 37) and COVID-19 patients with mild (n = 24), moderate (n = 23), and severe (n = 11) disease and at
convalescence (n = 80).
(G) tSNE projection of flow cytometry panel visualizing B cell subsets in PBMCs. Representative images for healthy individuals, severe COVID-19
patients, and convalescent patients. Key indicates cell subsets identified on the image.
(H) Cumulative data show frequency of CD27hiCD38hi plasmablasts in healthy controls (n = 38) and COVID-19 patients with mild (n = 23), moderate (n =
23), and severe (n = 12) disease and at convalescence (n = 81).
(I) Graph showing correlation between plasmablasts and IgG+ (left), IgA+ (center), or IgM+ (right) B cell frequencies in acute COVID-19 patients. Graphs
show individual patient data, with the bar representing median values.
In all graphs, open triangles represent SARS-CoV-2 PCR patients. *p < 0.05, **p < 0.01, ***p < 0.001, 1-way ANOVA with Kruskal-Wallis test with Dunn’s
post hoc testing for multiple comparisons or Spearman ranked coefficient correlation test.
See also Figures S1 and S2.
















































































































































































































































































































































































Figure 2. Acute alterations in CD4+ T cells and persistent alterations in CD8+ T cells during COVID-19
(A) Representative FACS plots showing CD45RA and CCR7 staining on CD4+ (gated CD3+CD8) and CD8+ (gated CD3+CD4) T cells.
(B and C) Graphs showing frequencies of (B) CD8+ and (C) CD4+ T cells that have a naive (CD45RA+CCR7+) and TEMRA (CD45RA+CCR7) phenotype in
healthy individuals (n = 44) and COVID-19 patients with mild (n = 18–19), moderate (n = 18), and severe (n = 8) disease and at up to 6 months of
convalescence (n = 83).
(D) Graphs showing frequencies of CD8+ and CD4+ T cells that stain positive for Ki-67 in healthy individuals (n = 28–30), and COVID-19 patients with mild
(n = 14), moderate (n = 11–13), and severe (n = 9) disease and at convalescence (n = 81).
(E–G) Graphs showing frequencies of (E) CD8+Perforin+ cells, (F) CD8+GranzymeB+ cells, and (G) CD8+CD107a+ cells and CD8+GranzymeB+ Ki-67+ cells
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OPEN ACCESS Clinical and Translational Reportin CD8+ T cells (Figure 2H), but reduced Ki-67+, CD107a+, and Ki-67+GranzymeB+
CD8+ T cells at convalescent compared to acute time points (Figure 2I). We also
noted a persistence of this cytotoxic profile in CD8+ T cells in a small subset of conva-
lescent patients examined beyond 6 months after hospital discharge. Obtaining a
second convalescent sample from the same patient at a later time point of convales-
cence demonstrated persistence of this cytotoxic program beyond 6 months
(Figure S1L).
In contrast to these phenotypic changes persisting in the CD8+ T cell compartment
up to, and potentially beyond, 6months of convalescence, alterations noted in acute
disease in CD4+ T cells were normalized in convalescent patients. There were no sig-
nificant changes in regulatory T cells (Tregs) across the disease trajectory (Figure 2J),
but during acute disease, there was an expansion in Tfh, defined as CD4+CXCR5+
PD-1+ICOS+ (Figure 2K). While an increase in Tfh has been reported previously in
acute COVID-19 patients,6,24–26 we show it was reduced in convalescent patients
(Figure 2K). This decrease in Tfh in convalescent patients occurred following hospital
discharge (Figure 2L) and could be identified when following the same patient from
acute disease into convalescence (Figure 2M). These data demonstrate changes in
the functional potential of CD8+ T cells up to 6 months following hospital discharge,
outlining the continued expression of a cytotoxic program.Lymphocytes from acute COVID-19 patients exhibit altered trafficking
molecule expression that is restored upon convalescence
Lymphopenia is a well-established hallmark of COVID-19 patients1,8; although the
drivers of peripheral blood lymphocyte loss remain unknown, altered trafficking
could contribute. Given the importance of appropriate coordination between im-
mune cells during an effective antiviral response and the implications of altered traf-
ficking molecule expression, we examined the expression of chemokine receptors
on lymphocytes during acute and convalescent COVID-19. B cells from acute
COVID-19 patients displayed a significantly reduced expression of chemokine re-
ceptors CXCR3, CXCR5, and the gut homingmolecule integrin b7, particularly in pa-
tients with more severe disease (Figures S2A–S2D). The expression of CXCR5 and
CXCR3 was largely normalized in convalescent patients regardless of acute disease
severity (Figure S2E).
Similar to B cells, CXCR5 and CXCR3 expression was substantially reduced in both
CD4+ and CD8+ T cells in acute COVID-19 patients (Figures S2F–S2K), but with b7
exhibiting no alterations in acute disease. This reduction in CXCR3 and CXCR5
occurred irrespective of acute disease severity (Figures S2L and S2M). The loss of
CXCR3 and CXCR5 expression was recovered on T cells from convalescent patients(H and I) Graphs track frequencies of (H) Perforin+ and GranzymeB+ and (I) Ki-67+, CD107a+, and GranzymeB+Ki-67+CD8+ T cells in the same COVID-19
patient at acute (gray circles) and convalescent (maroon circles) time points (n = 14).
(J) Graph shows frequencies of Tregs within CD4+ T cells of healthy individuals (n = 20) and COVID-19 patients with mild (n = 10), moderate (n = 12), and
severe (n = 8) disease and at convalescence (n = 82).
(K) Graph shows frequencies of Tfh within CD4+ T cells of healthy individuals (n = 34) and COVID-19 patients with mild (n = 12), moderate (n = 15), and
severe (n = 7) disease and at convalescence (n = 83).
(L) Graph shows frequencies of Tfh in individual acute COVID-19 patients with mild (n = 4), moderate (n = 5), and severe (n = 3) disease at their first and
last time points of hospitalization.
(M) Graph tracks frequency of Tfh CD4+ T cells in the same COVID-19 patient at acute (gray circles) and convalescent (maroon circles) time points (n =
14). Graphs show individual patient data, with the bar representing median values.
In all graphs, open triangles represent SARS-CoV-2 PCR patients. *p < 0.05, **p < 0.01, ***p < 0.001, 1-way ANOVA with Kruskal-Wallis test with Dunn’s
post hoc testing for multiple comparisons (for B–G and K) or Wilcoxon matched-pairs signed rank test (I and M).
See also Figures S1 and S2.






Figure 3. Changes in cytokine production by lymphocytes during acute and convalescent COVID-19
(A–C) Graphs showing frequencies of CD4+ T cells that stain positive for (A) IL-10, (B) IL-17, and (C) IFNg and TNF-a following 3-h stimulation with PMA
and ionomycin in healthy individuals (n = 25–30), acute COVID-19 patients (n = 29–33), and convalescent COVID-19 patients with normal (n = 55–57) or
abnormal chest X-ray findings (n = 25–26).
(D) Graphs showing frequencies of CD8+ T cells that stain positive for IFNg and TNF-a following 3-h stimulation with PMA and ionomycin in healthy
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OPEN ACCESS Clinical and Translational Report(Figures S2F, S2G, S2I, and S2J). In agreement with previous reports examining the
expression of CXCR5,6 our data outline reduced the expression of multiple traf-
ficking molecules on lymphocytes during acute COVID-19 that are mostly restored
upon convalescence. Reduced CXCR3 and CXCR5 expression could reflect reduced
homing of lymphocytes into lymph nodes and follicles, which have been reported to
contribute to immune dysfunction in other infections, such as advanced HIV.27–29
Here, we identify changes in chemokine receptor expression during acute disease
that are recovered upon convalescence.Alterations in lymphocyte cytokine potential in convalescent COVID-19
patients
To understand the impact of COVID-19 on the potential of lymphocytes to make
distinct cytokines, we stimulated PBMCs with phorbol myristrate acetate (PMA)
and ionomycin and examined cytokine production by T cells (see Figure S3A for
example staining). Unlike previously published studies probing antigen specificity
of T cells in COVID-19 patients,14,30 we more broadly assessed the potential of all
T cells in COVID-19 patients to secrete cytokines. This approach allowed us to assess
the impact of COVID-19 hospitalization on any subsequent immune response, as
opposed to the development of SARS-CoV2-specific memory. IL-10+ CD4+ T cells
were expanded in acute COVID-19 patients, but this was not observed in convales-
cent patients (Figure 3A). Normalization of IL-10 production from CD4+ T cells did
not occur during hospitalization, as a decrease in IL-10+CD4+ T cells was not evident
upon discharge (Figure S3B). As previously reported to occur in response to anti-
CD3 and anti-CD28 stimulation,31 PMA and ionomycin stimulation resulted in
increased IL-17+CD4+ T cells in COVID-19 patients (Figure 3B). Remarkably,
enhanced IL-17+CD4+ T cells persisted into convalescence. We next queried
whether the elevated production of IL-17 during convalescence was associated
with any specific clinical phenotypes. Increased IL-17+CD4+ T cells in convalescent
patients were seen irrespective of whether patients were stratified by the presenta-
tion of normal or abnormal chest X-rays (Figure 3B), reporting versus not reporting
increased fatigue, or based upon initial disease severity (Figure S3C).
Despite increased IL-10+ and IL-17+CD4+ T cells, neither CD4+ or CD8+ T cells from
acute COVID-19 patients exhibited altered proportions of cells staining positive for
the canonical Th1 cytokines interferon g (IFNg) or tumor necrosis factor a (TNF-a)
(Figures 3C and 3D). Although a previous study has reported that high proportions
of antigen-specific IFNg T cells are associated with reduced disease severity,26 our
observation is in line with other studies demonstrating that total peripheral T cell
populations exhibit no enhanced production of these cytokines despite ongoing dis-
ease6,32 and irrespective of acute disease severity (Figures S3D and S3E). In stark
contrast, both CD4+ and CD8+ T cells from convalescent COVID-19 patients(E and F) Graphs show frequencies of (E) CD4+ and (F) CD8+ T cells that stain positive for IFNg and TNF-a following 3-h stimulation with PMA and
ionomycin in convalescent COVID-19 patients who initially presented with mild (n = 13–14), moderate (n = 25–28), and severe (n = 34–41) disease.
(G and H) Graphs track frequencies of (G) CD4+ and (H) CD8+ T cells that stain positive for IFNg and TNF-a in the same COVID-19 patient at acute (gray
circles) and convalescent (maroon circles) time points (n = 14).
(I) Graphs showing frequencies of CD19+ B cells positive for IL-10, IL-6, and TNF-a following 48-h stimulation with CpGB in healthy individuals (n = 22–
27), acute COVID-19 patients (n = 22–32), and convalescent COVID-19 patients with normal (n = 52–54) or abnormal chest X-ray findings (n = 24–27).
(J) Graphs track frequencies of CD19+ B cells that stain positive for IL-10, IL-6, and TNF-a in the same COVID-19 patient at acute (gray circles) and
convalescent (maroon circles) time points (n = 11–14). Graphs show individual patient data, with the bar representing median values.
In all graphs, open triangles represent SARS-CoV-2 PCR patients. *p < 0.05, **p < 0.01, ***p < 0.001, 1-way ANOVA with Kruskal-Wallis test with Dunn’s
post hoc testing for multiple comparisons, except for graphs showing CD4+TNF-a+ and CD8+IFNg+ T cells in (E) and (F), where 1-way ANOVA with
Holm-Sidak post hoc test was used, or Wilcoxon matched-pairs signed rank test (G, H, and J).
See also Figures S3 and S4.
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OPEN ACCESSClinical and Translational Reportexhibited enhanced production of type 1 cytokines (Figures 3C and 3D). This in-
crease in cytokine production was not evident at hospital discharge (Figures S3F
and S3G). Increased type 1 cytokines occurred when stratifying convalescent pa-
tients by the presentation of normal or abnormal chest X-rays (Figures 3C and 3D)
and those reporting increased fatigue (Figure S3H). Of note, no significant increase
in IFNg+CD4+ T cells was seen when stratifying patients for fatigue. Increased pro-
duction of type 1 cytokines in convalescent patients was associated with COVID-
19 disease severity, apart from for IFNg+CD4+ T cells, as patients who hadmoderate
and severe disease showed significant increases in cytokine-positive cells relative to
controls (Figures 3E and 3F). As such, the increases seen in total convalescent pa-
tients could be due to increased proportions of patients who exhibited severe dis-
ease. However, comparing proportions of cytokine-positive cells in severe patients
at acute and convalescent time points still showed an elevation in cytokine-produc-
ing T cells, apart from for TNF-a+CD8+ T cells (Figures S3I and S3J). More important,
longitudinal data tracking the same patient across their acute and convalescent dis-
ease time points also showed increased production of these type 1 cytokines (except
for IFNg+TNF-a+CD4+ T cells) (Figures 3G and 3H). In a small subset of patients, we
also obtained a second convalescent sample after 6 months from hospital discharge.
In this small group, we noted unchanged proportions of cytokine-positive T cells,
suggesting the persistence of elevated cytokine production beyond 6 months (Fig-
ures S3K and S3L). These data fit with previous studies showing IFNg+ and TNF-a+
SARS-CoV-2-specific T cells in convalescent patients,14,30,33 but further outline
that altered cytokine potential is a general feature of all T cells during COVID-19
convalescence.
Next, to assess cytokine production by B cells, we stimulated PBMCs fromCOVID-19
patients with CpGB (a TLR9 agonist) for 48 h and measured cytokine expression by
flow cytometry. We observed a significant expansion of IL-6+ B cells in acute COVID-
19 patients and a trend toward a decrease in IL-10+ B cells, suggesting an imbalance
in B cells toward a more pro-inflammatory phenotype (Figures 3I and S4A–S4D). The
frequency of IL-6+ B cells was restored in convalescent patients and was not affected
by the presentation of normal or abnormal chest X-rays (Figure 3I) or fatigue (Fig-
ure S4D). Interestingly, B cell production of IL-10 was higher in convalescent patients
with a good clinical outcome compared to those with a poor outcome. Increased
proportions of IL-10+ B cells in convalescent patients with normal chest X-rays
compared to those with abnormal chest X-rays (Figure 3I) suggests a positive
outcome may be associated with the expansion of regulatory B cells. No significant
differences in the frequency of TNF-a+ B cells were observed in acute and convales-
cent COVID-19 patients (Figures 3I and S4D). Frequencies of cytokine-positive B
cells in both acute and convalescent patients were not affected by disease severity
(Figures S4E and S4F). Longitudinal analysis of individual patients from acute disease
into convalescence showed no change in either IL-6+ or TNF-a+ B cells, but it did
demonstrate a recovery of IL-10+ B cells upon convalescence (Figure 3J). Of note,
only 1 of 13 patients whose B cells were followed longitudinally exhibited an
abnormal chest X-ray at follow-up. These data demonstrate an expansion of IL-6+
B cells during acute disease and reduced proportions of IL-10+ B cells in convales-
cent patients with poor clinical outcomes.
Identification of COVID-19 convalescent immunotypes based on lymphocyte
parameters
Our data establish alterations in the lymphocyte compartment that persist up to
6 months post-hospital discharge in convalescent patients. To further probe
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OPEN ACCESSClinical and Translational Reportbased on T and B cell features. Unsupervised clustering revealed 3 groups of conva-
lescent patients with distinct compositions of lymphocyte signatures (Figure 4A).
Group 1 was associated with a high expression of trafficking molecules and
increased proportions of naive B and T cells; group 2 was characterized by high pro-
portions of IgA+ and IgG+ B cells and memory B cells (both switched and un-
switched); group 3 displayed increased cytotoxic T cells, CD8+ TEMRA, and type
1 cytokines by both CD8+ and CD4+ T cells. These data suggest the existence of sub-
groups of convalescent COVID-19 patients based on lymphocyte phenotypes. We
next queried whether these groups could identify convalescent patients based on
clinical outcome. Higher proportions of patients in group 3 presented with an
abnormal chest X-ray and reported breathlessness at their convalescent follow-up
(group 1: abnormal chest X-ray, 23.7%, and dyspnea, 43.2%; group 2: abnormal
chest X-ray, 26.3%, and dyspnea, 44.4%; group 3: abnormal chest X-ray, 62.5%,
and dyspnea, 62.5%). Examining characteristics of the patients within each group
(Figures 4B–4G), we noted that group 1 contained most patients who had had
mild disease, younger patients, and a greater proportion of female patients, indi-
cating that these parameters could be affecting this convalescent phenotype. In
contrast, we noted very little difference in the demographics or acute disease infor-
mation between patients in groups 2 and 3. For example, both had a similar propor-
tion of patients who had exhibited severe COVID-19 (group 2, 66.6%; group 3, 50%)
and similar proportions of males (group 2, 70.5%; group 3, 75%). Despite similar pa-
tient characteristics, these 2 patient groups present with distinct lymphocyte profiles
and different outcomes, with group 3 exhibiting the poorest clinical outcome
(abnormal chest X-ray, group 2, 26.3%; group 3, 62.5%). Our data provide an impor-
tant foundation for future work supporting the identification of hospitalized COVID-
19 patients at risk of developing long COVID symptoms. Our study can now be
expanded to explore additional clinical implications of COVID-19, ascertaining
whether specific clinical outcomes are associated with distinct convalescent patient
subgroups. These consequences can be ascertained as platforms such as the post-
hospitalization COVID-19 study (PHOSP-COVID) in the United Kingdom exist to sup-
port such future studies. Moreover, any future studies should also explore whether
the lymphocyte alterations defined here are specific to COVID-19 convalescence
or occur following hospitalization with any respiratory virus.
In summary, here, we report lymphocyte changes across the COVID-19 disease tra-
jectory into convalescence. Our data demonstrate a high degree of activation of a
cytotoxic program within CD8+ T cells during acute disease, as previously re-
ported.3,5,34 We extend these data by showing the persistence of this program
within circulating CD8+ T cells up to at least 6 months of convalescence. Whereas
previous studies have shown a persistence of low frequencies of SARS-CoV2-specific
CD8+ T cells with a cytotoxic profile,33 importantly, here, we show the elevation of
cytotoxic markers within total circulating CD8+ T cells. Although the specificity ofFigure 4. Distinct immune profiles emerge in previously hospitalized convalescent COVID-19 patients
(A) Heatmap of indicated immune parameters by row. Each column represents an individual convalescent COVID-19 patient. The patients were
clustered using one minus Pearson correlation hierarchical clustering. Significance was determined by 2-way ANOVA, followed by a Tukey’s multiple
comparison test. Asterisk next to lymphocyte characteristic indicates a significant difference between patient groups. Dominant immune characteristics
of each group are indicated at the bottom of the heatmap. Black and white squares indicate patients displaying a normal (white) or abnormal (black)
chest X-ray at follow-up.
(B–G) Graphs show patient characteristics and clinical details of convalescent COVID-19 patients in each of the 3 immune groups identified, specifically:
(B) age; (C) BMI; (D) sex; (E) severity of acute COVID-19 (with 1 being mild, 2 moderate and 3 severe); (F) length, in days, of hospitalization for acute
COVID-19; and (G) time, in days, from hospital discharge to follow-up of convalescent patients.
Graphs show individual patient data, with the bar representing median values. *p < 0.05, 1-way ANOVA with Kruskal-Wallis test with Dunn’s post hoc
testing for multiple comparisons.
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toxic potential would result in an altered T cell landscape that could affect tissue
integrity, depending on their trafficking capabilities and cytokine responsiveness.
Moreover, our data raise questions about the impact that this increase in cytotoxic
cells would have on subsequent infection, be that bacterial, viral, or fungal. The
importance of this question is further underscored by the elevated potential of total
CD8+ and CD4+ T cells to produce IFNg and TNF-a in convalescent patients, outlin-
ing a persistent alteration in cytokine potential that could be either beneficial or
detrimental to subsequent immune responses.
In contrast, altered B cell subsets in acutedisease are recovered upon convalescence.
Several recent studies have reported the detection of virus-specific antibodies for
several months post-recovery from SARS-CoV-2 infection.35–37 Here, we show that
circulating plasmablast frequencies correlate positively with IgA/IgG and negatively
with IgM, further supporting an expansion of class-switched antibodies in COVID-19
patients. In addition to secreting antibodies, B cells produce cytokines and are clas-
sified into effector (Beff; IL-6+ and TNF-a+) and regulatory B cell (Breg; IL-10+) subsets
based on the cytokines that they produce.38 Significant decreases in transitional B
cells, the precursors of human Bregs,39 along with IL-10+ B cells, suggest a loss of
immunosuppressive Bregs and an expansion of Beff cells in severe COVID-19 pa-
tients, as also observed in chronic inflammatory disorders such as systemic lupus er-
ythematosus (SLE) and rheumatoid arthritis (RA).39–41 Interestingly, the resolution of
lung pathology in COVID-19 patients was found to be associatedwith higher propor-
tions of IL-10+ B cells, suggesting that these cells could be important in suppressing
excess inflammation, and are associated with positive long-term outcomes.
In summary, we report phenotypic and functional alterations to B and T cells across
the trajectory of SARS-CoV-2 responses from acute disease requiring hospitalization
into convalescence, identifying immune alterations that persist in convalescent
COVID-19 patients for up to 6 months. Our study therefore identifies lymphocyte
changes in convalescent COVID-19 patients, which could have longer-term effects
on subsequent anti-pathogen or auto-inflammatory responses.Limitations of study
Our study has limitations, including the reduced number of samples from patients at
acute disease (n = 58) relative to those during convalescence (n = 83); in fact, for
someparameters, only 30 acute sampleswereexamined. Furthermore,disease severity
in the acute group did not match that in the convalescent group; the latter contained
more severe patients (acute = 22.4%; convalescence = 49.4%). In addition, only 14 pa-
tients were followed longitudinally from acute disease into convalescence. Our study
would have been significantly enhanced if we could have followed more individual pa-
tients. Our studywould have been further enhancedwere it possible to examine conva-
lescent patients at later time points—for example, 9 months and 1 year.STAR+METHODS
Detailed methods are provided in the online version of this paper and include the
following:
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Kerry, Sylvia Lui, Lijing Lin, Alex G. Mathioudakis, Joanne Mitchell, Clare Moizer, Ka-
trina Moore, Stuart Moss, Syed Murtuza Baker, Rob Oliver, Grace Padden, Christina
Parkinson, Michael Phuycharoen, Ananya Saha, Barbora Salcman, Nicholas A. Scott,
Seema Sharma, Jane Shaw, Joanne Shaw, Elizabeth Shepley, Lara Smith, Simon Ste-
phan, Ruth Stephens, Gael Tavernier, Rhys Tudge, Louis Wareing, Roanna Warren,
Thomas Williams, Lisa Willmore, and Mehwish Younas.
ACKNOWLEDGMENTS
This study was funded by the BBSRC (BB/M025977/1, to J.E.K. and BB/S01103X/1, to
T.N.S.), by the Lister Institute (Prize Fellowship to J.E.K.), by PTDF (SHS/1327/18, to
H.A.S.), the Wellcome Trust (202865/Z/16/Z, to T.H.), The Kennedy Trust for Rheuma-
tologyResearch (RapidResponseAward toJ.R.G.),VersusArthritis (F.A.M.andJ.E.K. stu-
dentship), and philanthropy awards from3MGlobalGiving (J.R.G. and T.H.) and theUni-
versity ofManchester COVID-19 fund (J.E.K. andM.M.). J.R.G. is the recipient of a Senior
Fellowship fundedbyThe Kennedy Trust for RheumatologyResearch. Thiswork alsowas
partly funded by UKRI/NIHR through the UK Coronavirus Immunology Consortium
(UK-CIC). This report is independent research supported by theNorthWest LungCentre
Charity and theNIHRManchesterClinical ResearchFacility atWythenshaweHospital.We
acknowledge the Manchester Allergy, Respiratory, and Thoracic Surgery Biobank and
thank the studyparticipants for their contribution. The views expressed in this publication
are those of the authors and not necessarily those of the NHS, the National Institute for
Health Research, or the Department of Health. Angela Simpson, Tim Felton, Paul Dark,
and Tracy Hussell are supported by the NIHR Manchester Biomedical Research Centre.
In addition, we would like to thank the following for technical and scientific discussions:
the Lydia Becker Institute of Immunologyand Inflammation, theUniversity ofManchester
Flow Cytometry Facility, The NIHR Respiratory TRC, the UK Coronavirus Immunology
Consortium, and PHOSP-COVID.
AUTHOR CONTRIBUTIONS
Conceptualization, J.E.K. and M.M.; methodology, J.E.K., M.M., J.R.G., and T.H.;
investigation, H.A.S., T.N.S., K.W., F.A.M., S.B.K., I.P., C.J., D.J.M., S.K., O.B.,Med 2, 720–735, June 11, 2021 733
ll
OPEN ACCESS Clinical and Translational ReportE.R.M., and the CIRCO investigators; formal analysis, I.P. and S.B.K.; resources,
S.B.K., L.P., A.U., N.D.B., P.D., C.E.B., S.B., T.F., and A.S.; data curation, S.B.K.;
writing – original draft, J.E.K. and M.M.; writing – review & editing, H.A.S., T.N.S.,
J.E.K., M.M., J.R.G., and T.H.; visualization, K.W.; supervision, J.E.K. and M.M.;
funding acquisition, J.E.K., M.M., J.R.G., and T.H.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: October 15, 2020
Revised: March 1, 2021
Accepted: March 19, 2021
Published: March 31, 2021REFERENCES1. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu,
Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020).
Clinical features of patients infected with 2019
novel coronavirus in Wuhan, China. Lancet 395,
497–506.
2. Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.H.,
Ou, C.Q., He, J.X., Liu, L., Shan, H., Lei, C.L.,
Hui, D.S.C., et al.; China Medical Treatment
Expert Group for Covid-19 (2020).
Clinical Characteristics of Coronavirus
Disease 2019 in China. N. Engl. J. Med. 382,
1708–1720.
3. Kuri-Cervantes, L., Pampena, M.B., Meng,
W., Rosenfeld, A.M., Ittner, C.A.G., Weisman,
A.R., Agyekum, R.S., Mathew, D., Baxter,
A.E., Vella, L.A., et al. (2020). Comprehensive
mapping of immune perturbations
associated with severe COVID-19. Sci.
Immunol. 5, eabd7114.
4. Lucas, C., Wong, P., Klein, J., Castro, T.B.R.,
Silva, J., Sundaram, M., Ellingson, M.K., Mao,
T., Oh, J.E., Israelow, B., et al.; Yale IMPACT
Team (2020). Longitudinal analyses reveal
immunological misfiring in severe COVID-19.
Nature 584, 463–469.
5. Mann, E.R., Menon, M., Knight, S.B., Konkel,
J.E., Jagger, C., Shaw, T.N., Krishnan, S.,
Rattray, M., Ustianowski, A., Bakerly, N.D.,
et al.; NIHR Respiratory TRC; CIRCO (2020).
Longitudinal immune profiling reveals
key myeloid signatures associated with
COVID-19. Sci. Immunol. 5, eabd6197.
6. Mathew, D., Giles, J.R., Baxter, A.E.,
Oldridge, D.A., Greenplate, A.R., Wu, J.E.,
Alanio, C., Kuri-Cervantes, L., Pampena,
M.B., D’Andrea, K., et al.; UPenn
COVID Processing Unit (2020). Deep
immune profiling of COVID-19 patients
reveals distinct immunotypes with
therapeutic implications. Science 369,
eabc8511.
7. Wilk, A.J., Rustagi, A., Zhao, N.Q., Roque, J.,
Martı́nez-Colón, G.J., McKechnie, J.L., Ivison,
G.T., Ranganath, T., Vergara, R., Hollis, T.,
et al. (2020). A single-cell atlas of the
peripheral immune response in patients
with severe COVID-19. Nat. Med. 26, 1070–
1076.
8. Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D.,
Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H.,734 Med 2, 720–735, June 11, 2021et al. (2020). Clinical and immunological
features of severe and moderate coronavirus
disease 2019. J. Clin. Invest. 130, 2620–2629.
9. Fraser, E. (2020). Long term respiratory
complications of covid-19. BMJ 370, m3001.
10. Williams, F.M.K., Muirhead, N., and Pariante, C.
(2020). Covid-19 and chronic fatigue. BMJ 370,
m2922.
11. Greenhalgh, T., Knight, M., A’Court, C.,
Buxton, M., and Husain, L. (2020). Management
of post-acute covid-19 in primary care. BMJ
370, m3026.
12. Rodda, L.B., Netland, J., Shehata, L., Pruner,
K.B., Morawski, P.A., Thouvenel, C.D.,
Takehara, K.K., Eggenberger, J., Hemann,
E.A., Waterman, H.R., et al. (2021). Functional
SARS-CoV-2-Specific Immune Memory
Persists after Mild COVID-19. Cell 184, 169–
183.e17.
13. Dan, J.M., Mateus, J., Kato, Y., Hastie, K.M., Yu,
E.D., Faliti, C.E., Grifoni, A., Ramirez, S.I.,
Haupt, S., Frazier, A., et al. (2021).
Immunological memory to SARS-CoV-2
assessed for up to 8 months after infection.
Science 371, eabf4063.
14. Peng, Y., Mentzer, A.J., Liu, G., Yao, X., Yin, Z.,
Dong, D., Dejnirattisai, W., Rostron, T., Supasa,
P., Liu, C., et al.; Oxford Immunology Network
Covid-19 Response T cell Consortium;
ISARIC4C Investigators (2020). Broad and
strongmemory CD4+ andCD8+ T cells induced
by SARS-CoV-2 in UK convalescent individuals
following COVID-19. Nat. Immunol. 21, 1336–
1345.
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KEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Human TruStain FcX (Fc Receptor Blocking
solution) (5ul/stain)
Biolegend Cat# 422302; RRID: AB_2818986
PE-Cyanine7 anti-human CD19 (clone: HIB19,
1 in 50)
Biolegend Cat# 302216; RRID: AB_314246
PE-Dazzle 594 anti-human CD27 (clone: M-
T271, 1 in 50)
Biolegend Cat# 356422; RRID: AB_2564101
PerCP-Cyanine 5.5 anti-human CD38 (clone:
HIT2, 1 in 50)
Biolegend Cat# 303522; RRID: AB_893314
Brilliant Violet 605 anti-human IgD (clone: IA6-
2, 1 in 50)
Biolegend Cat# 348232; RRID: AB_2563337
Brilliant Violet 421 anti-human IgG (clone:
M1310G05, 1 in 50)
Biolegend Cat# 410704; RRID: AB_2565626
Brilliant Violet 510 anti-human IgM (clone:
MHM-88, 1 in 50)
Biolegend Cat# 314522; RRID: AB_2562916
APC anti-human IgA (clone: REA1014, 1 in 100) Miltenyi Biotech Cat# 130-116-879; RRID: AB_2727739
Brilliant Violet 785 anti-human CD11c (clone:
3.9, 1 in 50)
Biolegend Cat# 301644; RRID: AB_2565779
PE anti-human CD86 (clone: BU63, 1 in 50) Biolegend Cat# 374206; RRID: AB_2721633
PE anti-human IL-6 (clone:MQ2-13A5, 1 in 100) Biolegend Cat# 501107; RRID: AB_315155
APC anti-human IL-10 (clone: JES3-19F1, 1 in
25)
Biolegend Cat# 506807; RRID: AB_315457
Brilliant Ultra Violet 395 anti-human TNFa
(clone: Mab11, 1 in 50)
BD Biosciences Cat# 563996; RRID: AB_2738533
Alexa Fluor 700 anti-human IL-17 (clone:
BL168, 1 in 50)
Biolegend Cat# 512318; RRID: AB_2124868
PE-Cyanine7 anti-human IFNg (clone: 4S.B3, 1
in 50)
Biolegend Cat# 502528; RRID: AB_2123323
Alexa Fluor 700 anti-human Ki-67 (clone: Ki-67,
1 in 50)
Biolegend Cat# 350530; RRID: AB_2564040
Brilliant Violet 510 anti-human CXCR3 (clone:
G025H7, 1 in 50)
Biolegend Cat# 353726; RRID: AB_2563642
APC anti-human CXCR5 (clone: J252D4, 1 in
50)
Biolegend Cat# 356907; RRID: AB_2561816
Brilliant Violet 605 anti-human b7 (clone:
FIB504, 1 in 50)
BD Biosciences Cat# 564284; RRID: AB_2738729
Brilliant Violet 650 anti-human b7 (clone:
FIB504, 1 in 50)
BD Biosciences Cat# 564285; RRID: AB_2738730
Alexa Fluor 488 anti-human Blimp1 (clone:
646702, 1 in 25)
R&D Systems Cat# IC36081G; RRID: AB_11129439
APC-eFluor 780 anti-human CD24 (clone:
eBioSN3, 1 in 50)
eBioscience Cat# 47-0247-42; RRID: AB_10735091
FITC anti-human CD56 (clone: 5.1H11, 1 in 50) Biolegend Cat# 362546; RRID: AB_2565964
Brilliant Violet 650 anti-human CD3 (clone:
OKT3, 1 in 50)
Biolegend Cat# 317324; RRID: AB_2563352
Brilliant Violet 605 anti-human CD3 (clone:
OKT3, 1 in 50)
Biolegend Cat# 317322; RRID: AB_2561911
Brilliant Ultra Violet 395 anti-human CD3
(clone: SK7, 1 in 50)
BD Biosciences Cat# 564001; RRID: AB_2744382
PerCP-Cyanine 5.5 anti-human CD4 (clone:
SK3, 1 in 50)
Biolegend Cat# 344608; RRID: AB_1953235
Alexa Fluor 700 anti-human CD4 (clone: SK3, 1
in 50)
Biolegend Cat# 344622; RRID: AB_2563150
Brilliant Violet 510 anti-human CD8 (clone:
SK1, 1 in 50)
Biolegend Cat# 344732; RRID: AB_2564624
Brilliant Violet 785 anti-human CD8 (clone:
SK1, 1 in 50)
Biolegend Cat# 344740; RRID: AB_2566202
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
PE-Dazzle 594 anti-human TCRgd (clone: B1, 1
in 50)
Biolegend Cat# 331226; RRID: AB_2565534
Alexa Fluor 488 anti-human ICOS (clone:
C398.4A, 1 in 50)
Biolegend Cat# 313514; RRID: AB_2122584
PE anti-human PD-1 (clone: EH12.2H7, 1 in 50) Biolegend Cat# 329906; RRID: AB_940483
APC-Cyanine7 anti-human CCR7 (clone:
G043H7, 1 in 50)
Biolegend Cat# 353212; RRID: AB_10916390
Brilliant Violet 605 anti-human CD45RA (clone:
HI100, 1 in 50)
Biolegend Cat# 304134; RRID: AB_2563814
Brilliant Violet 711 anti-human CD25 (clone:
BC96, 1 in 50)
Biolegend Cat# 302636; RRID: AB_2562910
Brilliant Violet 785 anti-human CD127 (clone:
A019D5, 1 in 50)
Biolegend Cat# 351330; RRID: AB_2563605
PE-Dazzle 594 anti-human CD107a (clone:
H4A3, 1 in 100)
Biolegend Cat# 328646; RRID: AB_2566115
Brilliant Violet 421 anti-human GranzymeB
(clone: QA18A28, 1 in 50)
Biolegend Cat# 396414; RRID: AB_2810603
PE-Cyanine7 anti-human Perforin (clone: dG9,
1 in 50)
Biolegend Cat# 308126; RRID: AB_2572049
Alexa Fluor 488 anti-human Foxp3 (clone:
236A/E7, 1 in 50)
eBioscience Cat# 53-4777-42; RRID: AB_10804652
Biological samples
Blood samples (hospitalised patients at acute
time point)
UK, This paper Table S1
Blood samples (hospitalised patients at 3-
8 months convalescence)
UK, This paper Table S2
Chemicals, peptides, and recombinant proteins
Foxp3/transcription Factor staining buffer Set ThermoFisher 00-5523-00
Brefeldin A Biolegend 420601
Stimulation cocktail ThermoFisher 00-4970-03
Zombie UV Fixable Viability kit Biolegend 423108
Zombie NIR Fixable Viability kit Biolegend 423106
UltraComp eBeads ThermoFisher 01-2222-42
PBS GIBCO 10010023
RPMI 1640 GIBCO 31870025
L-glutamine GIBCO A2916801
HEPES GIBCO 15630056




CpG (ODN 2006) Cambridge Bioscience HC4039-200NMOL
Ficoll Plaque Plus GE Healthcare GE17-1440-03
Software and algorithms
FlowJo Treestar https://www.flowjo.com/
GraphPad Prism GraphPad Software https://www.graphpad.com/
Other
SepMATE tubes - 50 StemCell Technologies 85460
ll
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Lead contact
Further information and requests for resources and information should be directed
to the Lead Contact, Joanne E. Konkel (Joanne.konkel@manchester.ac.uk).Materials availability
This study did not generate new unique reagents.Med 2, 720–735.e1–e4, June 11, 2021 e2
ll
OPEN ACCESS Clinical and Translational ReportData and code availability
All relevant data outputs are within the paper and supplemental information.
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Study design and participants
Two cohorts of patients were recruited fromManchester University Foundation Trust
(MFT), Salford Royal NHS Foundation Trust (SRFT) and Pennine Acute NHS Trust
(PAT) under the framework of the Manchester Allergy, Respiratory and Thoracic Sur-
gery (ManARTS) Biobank (study no M2020-88) for MFT or the Northern Care Alliance
Research Collection (NCARC) tissue biobank (study no NCA-009) for SRFT and PAT.
Ethical approval obtained from the National Research Ethics Service (REC reference
15/NW/0409 for ManARTS and 18/WA/0368 for NCARC). Informed consent was ob-
tained from each patient, clinical information was extracted from written/electronic
medical records including demographic data, presenting symptoms, comorbidities,
radiographic findings, vital signs, and laboratory data. Patients were included if they
tested positive for SARS-CoV-2 by reverse-transcriptase–polymerase-chain-reaction
(RT-PCR) on nasopharyngeal/oropharyngeal swabs or sputum during their in-patient
admission for COVID-19. Patients with negative nasopharyngeal RTPCR results were
also included if there was a high clinical suspicion of COVID-19, the radiological find-
ings supported the diagnosis, and there was no other explanation for symptoms. Pa-
tients were excluded if an alternative diagnosis was reached, where indeterminate
imaging findings were combined with negative SARS-CoV-2 nasopharyngeal (NP)
test, or there was another confounding acute illness not directly related to COVID-
19. The severity of disease was scored each day, based on criteria for escalation of
care (Table S3). Where severity of disease changed during admission, the highest
disease severity score was selected for classification. Peripheral blood samples
were collected within 7 days of hospital admission, at discharge and then at 3-
9 months post hospital discharge when patients returned to out-patient clinics.
Demographics and clinical information for acute and convalescent patients can be
found in Tables S1 and S2.
Healthy controls
Recruiting healthy individuals from the community for blood sampling during the
SARS-CoV-2 outbreak was not possible, and therefore we sampled frontline workers
fromNHS Trusts and University ofManchester staff with an age range that was similar
to our COVID-19 patients (age range 35-71; median age = 50.9; 52% males). All




Fresh blood samples fromCOVID-19 patients and healthy individuals were collected
in EDTA tubes. Blood was diluted 1:1 with PBS and layered gently on Ficoll-Paque in
SepMATE tubes (StemCell Technologies) followed by density gradient centrifuga-
tion. Cells were thoroughly washed and were either freshly stained for flow cytome-
try or are stored in 10% dimethyl sulfoxide (DMSO) in fetal bovine serum (FBS) at
150C.
Cell culture
Frozen PBMC were thawed, washed and resuspended in RPMI containing 10% FBS,
L-Glutamine, non-essential amino acids, HEPES, and penicillin plus streptomycin.
2.5 3 105 cells were stimulated with; (i) 2mL/ml of stimulation cocktail (eBioScience)e3 Med 2, 720–735.e1–e4, June 11, 2021
ll
OPEN ACCESSClinical and Translational Reportin the presence of 10 mg/ml Brefeldin A for three hours (T cells), (ii) 1 mM CpG for 48
hours followed by 2mL/ml of stimulation cocktail (eBioScience) in the presence of
10 mg/ml Brefeldin A in the last four hours (B cells). Following stimulation cells
were washed and stained for flow cytometric analysis.Flow cytometry
PBMCs (fresh/thawed/stimulated) were stained with fluorophore conjugated anti-
bodies (see Key resources table) and viability dyes. Samples were acquired on an
LSRFortessa cell analyzer (Becon Dickinson) and analyzed using FlowJo (TreeStar).QUANTIFICATION AND STATISTICAL ANALYSIS
Clustering of T and B cell phenotypes
T cell and B cell data were scaled using unit variance scaling, clustered and graphed
using correlation distance and average linkage on the heatmap tool on ClustVis.42Statistics
Results are presented as individual data points with medians. Normality tests were
performed on all datasets. Groups were compared using an unpairedMann-Whitney
test for healthy individuals versus COVID-19 patients, one-way ANOVA with Holm-
Sidak post hoc testing (normal distribution) or Kruskal-Wallis test with Dunn’s post
hoc testing (failing normality testing) for multiple comparisons, or Spearman’s rank
correlation coefficient test for correlation of separate parameters within the
COVID-19 patient group, using Prism 8 software (GraphPad). In all cases, a p value
of % 0.05 was considered significant. Where no statistical difference is shown there
was no significant difference. Details of statistical tests and definitions of n can be
found in each figure legend.Med 2, 720–735.e1–e4, June 11, 2021 e4
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Supplemental Table 1. Clinical characteristics of acute COVID-19 patients, Related to 
Figures 1-4. Data are median (IQR)m , wherem is the number of missing data points, n (%) or 
n/N (%), where N is the total number with available data. PE, pulmonary embolism, AKI, Acute 




 Overall (58) Mild (22) Moderate (23) Severe (13) 
Age 58.5 (49.5-71) 58 (45-71) 58 (50-66.5) 67 (55-74) 
Gender     
     Male 36/58 (62.1%) 13/22 (59.1%) 13/23 (56.5%) 10/13 (77%) 
     Female 22/58 (37.9%) 9/22 (40.9%) 10/23 (43.5%) 3/13 (23%) 
BMI 28.5 (25.2-30.6)14  27.8 (23.2-33.1)8  29 (26.8-30.3)3  27.6 (25.4-30.2)3  
Day of admission recruited 2 (2-3) 3 (2-4.75) 2 (2-3) 2 (2-3) 
Medical History    
     Diabetes 13/58 (22.41%) 6/22 (27.27%) 2/23 (8.7%) 5/13 (38.46%) 
     Ischaemic Heart Disease 8/58 (13.79%) 3/22 (13.64%) 2/23 (8.7%) 3/13 (23.08%) 
     Hypertension 20/58 (34.48%) 6/22 (27.27%) 9/23 (39.13%) 5/13 (38.46%) 
     COPD 11/58 (18.97%) 5/22 (22.73%) 4/23 (17.39%) 2/13 (15.38%) 
     Asthma 9/58 (15.52%) 4/22 (18.18%) 4/23 (17.39%) 1/13 (7.69%) 
     Malignancy 5/58 (8.6%) 0/22 (0%) 2/23 (8.7%) 3/13 (23%) 
Differential counts on admission (x 109/L)     
     Total white cell count 7.1 (6-10)9  6.85 (5.55-8.42)4  7.3 (6.3-10)2  7.25 (6.55-10.02)3  
     Lymphocytes 1 (0.82-1.5)9 1.2 (0.92-1.77)4 0.9 (0.8-1.5)2 0.9 (0.82-0.98)3 
     Neutrophils 5.3 (4.4-8)9 5.15 (3.8-7.05)4 5.5 (4.7-7.7)2 6.25 (4.82-8.62)3 
     Monocytes 0.4 (0.2-0.6)9 0.25 (0.2-0.73)4 0.5 (0.4-0.7)2 0.35 (0.3-0.57)3 
Other inpatient investigations    
     Positive SARS CoV2 PCR 49/58 (84%) 18/22 (81%) 20/23 (87%) 11/13 (85%) 
     Highest CRP (mg/L) 144 (83.9-226) 99 (35-176) 131 (86.5-195.6) 256 (198-283) 
Chest Imaging     
     Bilateral opacification 49/56 (87.5%) 14/20 (70%) 22/23 (95.7%) 13/13 (100%) 
     Unilateral opacification 3/56 (5.4%) 2/20 (10%) 1/23 (4.3%) 0/13 (0%) 
     Clear 4/56 (7.1%) 4/20 (20%) 0/23 (0%) 0/13 (0%) 
Outcome     
     Length of stay (days) 6 (4-11.3)2  5.5 (3.3-9.2) 6 (4-10)2  10 (6-13) 











Supplemental Table 2. Clinical characteristics of convalescent COVID-19 patients 
Related to Figures 1-4. Data are median (IQR)m , wherem is the number of missing data points, 
n (%) or n/N (%), where N is the total number with available data. PE, pulmonary embolism, 
AKI, Acute kidney injury. a Admission observations. 
Convalescent Patients 
 Overall (83) Mild (15) Moderate (27) Severe (41) 
Age (years) 60 (51 - 66.5) 51 (45 - 59.54) 60 (51.5 - 71) 60 (55.63 - 66) 
Gender     
     Male 51/83 (61.4%) 10/15 (66.7%) 14/27 (51.9%) 27/41 (65.9%) 
     Female 32/83 (38.6%) 5/15 (33.3%) 13/27 (48.1%) 14/41 (34.1%) 
BMI 31 (28.7 - 34.7)31  34.8 (31.9 - 38.4)5  30.9 (28.8 - 34.6)13  29.6 (28.5 - 33.1)13  
Medical History     
     Diabetes 21/83 (25.3%) 4/15 (26.67%) 9/27 (33.33%) 8/41 (19.51%) 
     Ischaemic heart disease 17/83 (20.48%) 2/15 (13.33%) 12/27 (44.44%) 3/41 (7.32%) 
     Hypertension 32/83 (38.55%) 3/15 (20%) 13/27 (48.15%) 16/41 (39.02%) 
     COPD 14/83 (16.87%) 3/15 (20%) 9/27 (33.33%) 2/41 (4.88%) 
     Asthma 30/83 (36.14%) 7/15 (46.67%) 9/27 (33.33%) 14/41 (34.15%) 
     Malignancy 5/83 (6.02%) 0/15 (0%) 3/27 (11.1%) 2/41 (4.9%) 
ACUTE ADMISSION  
Differential blood counts on acute admission (x109/L)  
     Total white cell count 7.3 (5.77 - 10.1) 11  6.1 (4.8 - 7.5) 2 6.65 (5.63 - 9.55) 7 8.7 (6.8 - 11.35)2 
     Lymphocytes 0.89 (0.7 - 1.21) 11 1.1 (0.86 - 1.63) 2 0.98 (0.73 - 1.42) 7 0.8 (0.62 - 0.95)2 
     Neutrophils 5.99 (4.13 - 8.75) 11 4.04 (3.7 - 5.7) 2 4.81 (4.04 - 7.68) 7 7.03 (5.34 - 10.2)2 
     Monocytes 0.4 (0.27 - 0.56) 11 0.27 (0.23 - 0.55) 2 0.48 (0.3 - 0.6) 7 0.4 (0.3 - 0.52)2 
Other inpatient investigations   
     Positive SARS CoV2 test 78/83 (94%) 15/15 (100%) 25/27 (92.6%) 38/41 (92.7%) 
     Highest CRP (mg/L) 135 (66 - 245.5)3  50 (26.5 - 88.5) 113 (70 - 151.5)1  256 (131 - 330)2  
Chest imaging    
     Bilateral opacification 59/64 (92.1%) 7/9 (77.8%) 21/23 (91.3%) 31/32 (96.9%) 
     Unilateral opacification 4/64 (6.3%) 1/9 (11.1%) 2/23 (8.7%) 1/32 (3.1%) 
     Clear 1/64 (1.6%) 1/9 (11.1%) 0/23 (0%) 0/32 (0%) 
Outcome     
     Length of stay (days) 11 (5.5 – 21.5) 2 (1 - 5.5) 7 (4.5 - 13) 20 (13 - 39) 
CONVALESCENCE    
Admission to follow up (days) 158 (116.5 - 184.5) 174 (140.5 - 185) 140 (105 - 171.5) 155 (126 - 192) 
Discharge to follow up (days) 131 (90 - 178) 169 (138.5 - 181.5) 125 (95.5 - 165) 117 (87 - 180) 
Symptoms and investigations at follow up     
     Dyspnoea 38/82 (46.34%) 6/15 (40%) 16/27 (59.26%) 16/40 (40%) 
     Resolved CXR 55/83 (66.3%) 12/15 (80%) 19/27 (70.4%) 24/41 (58.5%) 






Supplemental Table 3. Patient categorisation Information Related to Figures 1-4. Criteria 
for patient stratification. NIV, non-invasive ventilation; CPAP, continuous positive airway 
pressure; ICU, intensive care.  
Severity Score Criteria 
Mild - <3l or 28% supplemental oxygen required to maintain oxygen 
saturations.  
- Managed in a ward based environment.  
Moderate -  Breathless  
-  <10l or <60% supplemental oxygen required to maintain oxygen  
saturations.  
-  Managed in a ward based environment.  
-  Chronic NIV or CPAP (home use) or acute NIV for COPD. 
Severe Any of:  
-  >10l or 60% supplemental oxygen required to maintain oxygen  
saturations.  
-  Use of acute NIV (not for COPD)  

























































































































































































































































r  = 0.1716
p = 0.1331






r  = 0.3215
**p = 0.0041





































Supplemental Figure 1. T and B cell subsets in hospitalized COVID-19 patients, Related 
to Figures 1 and 2. (A) Representative FACS plots showing Ki-67 staining on CD19+ B cells. 
(B) Representative FACS plots showing the gating strategy for CD27hiCD38hi plasmablasts. 
(C) Representative FACS plots gated on CD19+  B cells staining positive for IgG, IgM or 
IgA.(D) Graphs showing correlation between plasmablasts and IgG+ (left), IgA+ (middle) or 
IgM+ (right) B cell frequencies in convalescent COVID-19 patients (n=78) . (E,F) Graphs track 
frequencies of (E) Ki67+ B cells, plasmablasts, transitional (CD24hiCD38hi) B cells, and (F) 
CD27-IgD- B cells in the same COVID-19 patient at acute (grey circles) and convalescent 
(maroon circles) time-points (n=14). (G) Representative FACS plots showing Ki-67 staining 
on CD4+ and CD8+ T cells. (H,I) Representative FACS plots showing CD8+ T cells staining 
positive for (H) GranzymeB and (I) CD107a. (J) Representative FACS plots gated on 
CD3+CD4+CD127lo/neg T cells staining positive for CD25 and foxp3. (K) Representative FACS 
plots showing gating to identify Tfh cells (CD3+CD4+PD- 1+CXCR5+ ICOS+). (L) Graphs track 
frequencies of CD8+ T cells which are perforin+ and granzymeB+  in the same COVID-19 
patient at convalescent time-points pre (1) and post (2) 6 months since hospital discharge 





















































































































































































































































































































































































Supplemental Figure 2. Altered expression of migratory markers in acute but not 
convalescent COVID-19 patients, Related to Figures 1 and 2. (A-C) Representative flow 
cytometry plots and graphs showing frequencies of B cells expressing (A) CXCR5, (B) CXCR3 
and (C) b7 in healthy individuals (n=19-21), acute (n=21-34) and convalescent (n=81) COVID-
19 patients. (D) Graphs showing frequencies of B cells expressing CXCR3, CXCR5 and b7 in 
healthy individuals (n=19) and acute COVID-19 patients with mild (n=7-11), moderate (n=7-
10) and severe (n=5-9) disease. (E) Graphs showing frequencies of B cells staining positive 
for CXCR3, CXCR5 and b7 in healthy individuals (n=19-21) and convalescent COVID-19 
patients which initially presented with mild (n=13), moderate (n=26) and severe (n=41) 
disease. (F-H) Graphs showing frequencies of CD4+ cells positive for (F) CXCR5, (G) CXCR3 
and (H) b7 in healthy individuals (n=25-29), acute (n=26-27) and convalescent (n=80-83) 
COVID-19 patients. (I-K) Graphs showing frequencies of CD8+ cells positive for (I) CXCR5, 
(J) CXCR3 and (K) b7 in healthy individuals (n=25-29), acute (n=27-28) and convalescent 
(n=80-81) COVID-19 patients. (L,M) Graphs showing frequencies of (L) CD4+ and (M) CD8+ 
T cells staining positive for CXCR3 and CXCR5 in healthy individuals (n=25-29) and acute 
COVID-19 patients with mild (n=8-10), moderate (n=8) and severe (n=6-8) disease. Graphs 
show individual patient data, with the bar representing median values. In all graphs, triangles 
represent SARS-CoV-2 PCR-negative patients. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, 
one-way ANOVA with Holm-Sidak post-hoc testing (A-E, K and L (CXCR5)) or Kruskal-Wallis 
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Supplemental Figure 3. Long-lasting changes in type-I cytokine production T cells in 
convalescent COVID-19 patients, Related to Figure 3. (A) Representative FACS plots 
showing example staining for cytokine+ CD4+ and CD8+ T cells. (B) Graph shows frequency 
of IL-10+CD4+ T cells following 3 hour stimulation with PMA and ionomycin in acute COVID-
19 patients at the first and last time points of hospitalization. (C) Graph show frequencies of 
IL-17+CD4+ T cells following 3 hour stimulation with PMA and ionomycin in healthy individuals 
(n=22-30), acute COVID-19 patients (n=31) and convalescent COVID-19 patients stratified by 
fatigue reporting (not reporting (n=50) and reporting (n=20) enhanced fatigue) and mild (n=14), 
moderate (n=27) and severe (n=36) acute disease severity. (D, E) Graphs show frequencies 
of (D) CD4+ and (E) CD8+ T cells which stain positive for IFNg and TNFa following 3 hour 
stimulation with PMA and ionomycin in healthy individuals (n=14) and acute COVID-19 
patients with mild (n=10-11), moderate (n=12) and severe (n=7) disease. (F, G) Graphs show 
frequencies of (F) CD4+ and (G) CD8+ T cells that stain positive for IFNg and TNFa following 
3 hour stimulation with PMA and ionomycin in acute COVID-19 patients at the first and last 
time points of hospitalization. (H) Graphs show frequencies of CD4+ and CD8+ T cells which 
stain positive for IFNg and TNFa following 3 hour stimulation with PMA and ionomycin in 
healthy individuals (n=28-30), acute COVID-19 patients (n=24-33) and convalescent COVID-
19 patients not reporting (n=44-49) and reporting (n=20-21) enhanced fatigue. (I, J) Graphs 
show frequencies of CD4+ and CD8+ T cells which stain positive for IFNg and TNFa in all 
severe COVID-19 patients at acute (grey) and convalescent (maroon) time-points. (K, L) 
Graphs track frequencies of CD4+ and CD8+ T cells which stain positive for IFNg and TNFa 
following 3 hour stimulation with PMA and ionomycin in the same COVID-19 patient at 
convalescent time-points pre (1) and post (2) 6 months since hospital discharge (n=4-6). 
Graphs show individual patient data, with the bar representing median values. In all graphs, 
triangles represent SARS-CoV-2 PCR-negative patients. *p<0.05, **p<0.01, ***p<0.001, one-
way ANOVA with Kruskal-Wallis test with Dunn’s post-hoc testing for multiple comparisons 
(except for graphs showing CD4+TNFa+ and CD8+TNFa+ T cells in D and E where One-way 



















































































































































































Supplemental Figure 4. Cytokine production by B cells from acute and convalescent 
COVID-19 patients, Related to Figure 3. (A-C) Representative flow cytometry plots showing 
gating strategy of CD19+ B cells positive for IL-10, IL-6 and TNFa following 48 hour stimulation 
with CpGB. (D) Graphs show frequencies of CD19+ B cells staining positive IL-10, IL-6 and 
TNFa  following 48 hour stimulation with CpGC in healthy individuals (n=22-27), acute COVID-
19 patients (n=22-37) and convalescent COVID-19 patients not reporting (n=36-38) and 
reporting (n=15-17) enhanced fatigue. (E) Graphs show frequencies CD19+ B cells staining 
positive for IL-10, IL-6 and TNFa in healthy individuals (n=22-23), and convalescent COVID-
19 patients which initially presented with mild (n=12-13), moderate (n=25-26) and severe 
(n=41) disease. (F) Graphs show frequencies CD19+ B cells staining positive for IL-10, IL-6 
and TNFa in healthy individuals (n=11-13), and acute COVID-19 patients with mild (n=8-9), 
moderate (n=6) and severe (n=6) disease. Graphs show individual patient data, with the bar 
representing median values. *p<0.05, one-way ANOVA with Kruskal-Wallis test with Dunn’s 
post-hoc testing for multiple comparisons. 
 
 
 
